24,705 Shares in Amgen Inc. $AMGN Acquired by Nordwand Advisors LLC

Nordwand Advisors LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 24,705 shares of the medical research company’s stock, valued at approximately $6,898,000. Amgen comprises about 1.1% of Nordwand Advisors LLC’s investment portfolio, making the stock its 25th largest holding.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Brighton Jones LLC increased its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Abel Hall LLC purchased a new stake in Amgen during the first quarter worth approximately $232,000. IFP Advisors Inc boosted its holdings in Amgen by 13.3% in the first quarter. IFP Advisors Inc now owns 6,911 shares of the medical research company’s stock valued at $2,153,000 after purchasing an additional 809 shares in the last quarter. Atlantic Union Bankshares Corp increased its stake in Amgen by 1.3% in the first quarter. Atlantic Union Bankshares Corp now owns 4,016 shares of the medical research company’s stock valued at $1,251,000 after purchasing an additional 52 shares during the last quarter. Finally, Lindbrook Capital LLC increased its stake in Amgen by 20.5% in the first quarter. Lindbrook Capital LLC now owns 2,710 shares of the medical research company’s stock valued at $844,000 after purchasing an additional 461 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 9,036 shares of company stock valued at $2,992,594. Company insiders own 0.76% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup boosted their price objective on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research report on Tuesday, November 11th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Wells Fargo & Company lifted their target price on Amgen from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Guggenheim boosted their target price on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $314.05.

Amgen Trading Up 1.5%

Shares of Amgen stock opened at $341.71 on Tuesday. The company’s fifty day moving average is $296.14 and its two-hundred day moving average is $290.80. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $345.84. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company has a market capitalization of $184.00 billion, a P/E ratio of 27.94, a PEG ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the prior year, the firm earned $5.58 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is 73.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.